34-20B-20. Depressants specifically included in Schedule III.

Any material, compound, mixture, or preparation is included in Schedule III that contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:

(1)    Any substance that contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances that are specifically listed in other schedules;

(2)    Chloral betaine;

(3)    Chloral hydrate;

(4)    Chlorhexadol;

(5)    Lysergic acid;

(6)    Lysergic acid amide;

(7)    Methyprylon;

(8)    Sulfondiethylmethane;

(9)    Sulfonethylmethane;

(10)    Sulfonmethane;

(11)    Amobarbital, pentobarbital, and secobarbital in suppository dosage form;

(12)    Gamma hydroxy butyrate;

(13)    Dronabinol in sesame oil and encapsulated in a gelatin capsule in a drug product approved for marketing by the United States Food and Drug Administration;

(14)    Buprenorphine;

(15)    Embutramide;

(16)    Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl) benzonitrile], including its salts, isomers, and salts of isomers.

Source: SL 1970, ch 229, § 8 (c) (1); SDCL Supp, § 39-17-63; SL 1973, ch 260; SL 1979, ch 238, § 2; SL 1980, ch 240, § 1; SL 1992, ch 245, § 2; SL 1993, ch 247, § 4; SL 1999, ch 174, § 1; SL 2000, ch 170, § 2; SL 2003, ch 183, § 3; SL 2007, ch 194, § 2, eff. Feb. 1, 2007; SL 2014, ch 165, § 2, eff. Feb. 10, 2014; SL 2018, ch 203, § 4, eff. Feb. 8, 2018.



SDLRC - Codified Law 34-20B-20 - Depressants specifically included in Schedule III.

34-20B-20.1. Gamma hydroxyl butyrate defined.

For the purposes of § 34-20B-20, the term, gamma hydroxyl butyrate, includes gamma-butyrolactone, 1,4-butanediol or any other substances which convert to gamma hydroxyl butyrate upon ingestion. However, the term does not include any product which is lawfully used for mechanical, industrial, manufacturing, or scientific purposes.

Source: SL 2006, ch 180, § 1.



SDLRC - Codified Law 34-20B-20 - Depressants specifically included in Schedule III.

34-20B-20.2. Xylazine--Permissible uses.    

Any material, compound, mixture, or preparation that contains xylazine is a Schedule III controlled drug or substance, except in the following cases:

(1)    Dispensing, prescribing, or administering, to an animal, a drug containing xylazine that has been approved by the United States secretary of health and human services under 21 U.S.C. § 360b (January 1, 2024);

(2)    Dispensing, prescribing, or administering xylazine to an animal that is permissible under 21 U.S.C. § 360b(a)(4) (January 1, 2024);

(3)    Manufacturing, distributing, or using xylazine as an active pharmaceutical ingredient for manufacturing an animal drug:

(a)    Approved under 21 U.S.C. § 360b (January 1, 2024); or

(b)    Issued an investigation use exemption under 21 U.S.C. § 360b(j) (January 1, 2024);

(4)    Manufacturing, distributing, or using a xylazine bulk chemical for pharmaceutical compounding by a licensed pharmacist or veterinarian; or

(5)    Any other use approved or permissible under 21 U.S.C. § 301, et seq. (January 1, 2024).

Source: SL 2024, ch 131, § 1, eff. Feb. 12, 2024.